دورية أكاديمية
Taking cues from convalescence to improve vaccines against hepatitis C virus.
| العنوان: | Taking cues from convalescence to improve vaccines against hepatitis C virus. |
|---|---|
| المؤلفون: | Sreekumar BK, Taha TY, Ott M |
| المصدر: | The Journal of clinical investigation [J Clin Invest] 2022 Aug 01; Vol. 132 (15). |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Comment |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1999- : Ann Arbor, MI : American Society for Clinical Investigation Original Publication: New Haven [etc.] American Society for Clinical Investigation. |
| مواضيع طبية MeSH: | Hepatitis C* , Hepatitis C, Chronic* , Vaccines*/metabolism , Viral Hepatitis Vaccines*, Antibodies, Neutralizing ; Antiviral Agents ; Broadly Neutralizing Antibodies ; Convalescence ; Cues ; Hepacivirus ; Hepatitis C Antibodies ; Humans ; Viral Envelope Proteins |
| مستخلص: | Hepatitis C virus (HCV) infection remains a worldwide public health issue despite direct-acting antivirals. A substantial proportion of infected individuals (15%-45%) spontaneously clear repeated HCV infections with genetically different viruses by generating broadly neutralizing antibodies (bNAbs). However, translating this response into an effective vaccine strategy has been unsuccessful. In this issue of the JCI, Frumento and colleagues report on their study of bNAb evolution longitudinally in convalescent individuals with repeated infections. Using pseudotyped viruses, well-characterized monoclonal antibodies, and complex modeling, the authors show that multiple exposures to antigenically related, antibody-sensitive viral envelope proteins induced potent bNAbs. This work provides valuable insight into the best strategies for developing HCV vaccines in the future that may successfully reproduce the immunity induced during natural exposures. |
| التعليقات: | Comment on: J Clin Invest. 2022 Aug 1;132(15):. (PMID: 35588376) |
| References: | J Clin Invest. 2022 Aug 1;132(15):. (PMID: 35588376) Methods Mol Biol. 2019;1911:33-45. (PMID: 30593616) N Engl J Med. 2021 Feb 11;384(6):541-549. (PMID: 33567193) Lancet Public Health. 2021 May;6(5):e309-e323. (PMID: 33780656) Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):6025-30. (PMID: 17392433) Open Forum Infect Dis. 2019 Feb 22;6(3):ofz076. (PMID: 30949527) Gastroenterology. 2010 Jan;138(1):315-24. (PMID: 19782080) Nat Med. 2008 Jan;14(1):25-7. (PMID: 18064037) J Virol. 2004 Feb;78(3):1575-81. (PMID: 14722311) Cell Host Microbe. 2018 Nov 14;24(5):717-730.e5. (PMID: 30439341) Curr Epidemiol Rep. 2017 Jun;4(2):174-185. (PMID: 28785531) PLoS Pathog. 2012;8(8):e1002895. (PMID: 22952447) Hepatology. 2014 Jun;59(6):2140-51. (PMID: 24425349) Vaccine. 2010 Aug 31;28(38):6367-73. (PMID: 20619382) Viruses. 2015 Jul 17;7(7):3974-94. (PMID: 26193306) Viruses. 2018 Nov 21;10(11):. (PMID: 30469363) Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10149-54. (PMID: 15220475) Hepatology. 2016 Dec;64(6):1922-1933. (PMID: 27641232) |
| معلومات مُعتمدة: | P30 AI027763 United States AI NIAID NIH HHS; R01 AI097552 United States AI NIAID NIH HHS |
| المشرفين على المادة: | 0 (Antibodies, Neutralizing) 0 (Antiviral Agents) 0 (Broadly Neutralizing Antibodies) 0 (Hepatitis C Antibodies) 0 (Vaccines) 0 (Viral Envelope Proteins) 0 (Viral Hepatitis Vaccines) |
| تواريخ الأحداث: | Date Created: 20220801 Date Completed: 20220802 Latest Revision: 20220923 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC9337820 |
| DOI: | 10.1172/JCI161819 |
| PMID: | 35912856 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!